如何治疗对血小板输注无效的患者
本文综述了血小板输注无效(PR)的诊断与管理挑战,其病因分为免疫性与非免疫性,免疫性PR主要由I类HLA抗体引起。文章评估了现有支持治疗选择的数据,指出HLA配合性血小板的临床获益尚不明确,并识别了研究空白。
要点
- 血小板输注无效需高度怀疑免疫性病因并启动同种免疫检测,主要罪魁为I类HLA抗体。
- 免疫性PR的诊断方法随新技术而改变,但其临床意义与解读尚无定论。
- 提供HLA配合性血小板需输血服务与临床团队密切协调,但对临床结局的真实影响尚不明确。
核心结论
- 本文综述了血小板输注无效的诊断与管理挑战,评估了现有支持治疗选择的数据,并识别了研究空白。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 血小板输注无效的病因可 broadly 分为免疫性与非免疫性两类。
- 免疫性血小板输注无效的主要原因是I类HLA抗体的产生。
- 免疫性PR的诊断方法近年因新技术而改变,但其临床意义与解读问题尚未得到确切解答。
- 提供HLA配合性血小板对临床结局的真实影响尚不明确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.
引用
- Nahirniak S, Nadarajan V, Stanworth SJ, et al. How I treat patients who are refractory to platelet transfusions. Blood. 2025. PMID: 39970326. doi:10.1182/blood.2023022883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。